{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:56:39Z","timestamp":1793717799513,"version":"4.6.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cannabis Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Since its initial approval in 1992, medical cannabis (MC) in Israel has undergone extensive regulatory and structural transformation. This study aims to present the most comprehensive retrospective analysis to date of the evolving MC policy framework in Israel and its impact on patient access, prescribing patterns, and treatment characteristics from 2011 to 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study included a longitudinal review and secondary analysis of monthly Israeli Medical Cannabis Unit (IMCU) reports, covering key parameters such as the number of active licenses, indications, dosage patterns, product types, healthcare provider involvement, and importation data. Regulatory milestones and reforms were mapped to observed shifts in these parameters, with particular attention to the transition to per-product pricing (2019), the decentralization of prescription authority to trained physicians (2020), and the Health Maintenance Organization (HMO)-led prescribing reform (2024).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The number of active MC licenses increased markedly by over 4,400% from 3,097 in 2011 to a peak of 140,483 in January 2024. This growth coincided with expanded indications, broader pharmacy access, and prescribing authority beyond IMCU physicians. The 2024 HMO-led reform, followed by a 7.5% gradual decline to 129,900 active MC licenses and prescriptions on March 2025, alongside incomplete reporting of prescription indications data. This decline is consistent with this study hypothesis of stricter HMO gatekeeping and transition frictions. The most frequently approved indication was chronic non-cancer pain (CNCP) (increasing from 53 to 63%), with substantial, constant growth of\u2009~\u200989% (from 9 to 17%) in the second most common indication, post-traumatic stress-disorder. Approved monthly dosages shifted significantly: the share of patients receiving 50gr\/month rose by\u2009~\u2009108% and 60gr\/month by\u2009~\u2009117%, while the 40gr\/month category consistently comprised\u2009~\u200922\u201325% of active patient licenses. Product form trends were also notable: flower-based MC products accounted for over 94% of usage by 2025. At its peak, the estimated annual market value of MC products ranged between $252\u2013$684 million.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Israel\u2019s MC program reflects a dynamic interplay between policy reforms and patient treatment patterns. While preliminary MC medicalization improved access, recent decentralization efforts have introduced new challenges related to oversight and data transparency, plausibly reflecting stricter HMO gatekeeping, transition frictions, and the post-investigation non-renewal of irregular licenses (hypothesis given current data gaps), that may be associated with a decline in active MC licenses. The findings underscore the importance of maintaining consistent national reporting standards to guide evidence-based MC policy and clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42238-025-00344-1","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T04:12:22Z","timestamp":1763007142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Medical cannabis in Israel: a comprehensive review of trends and regulations, 2011\u20132025"],"prefix":"10.1186","volume":"7","author":[{"given":"Joshua","family":"Aviram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"344_CR1","doi-asserted-by":"publisher","unstructured":"Aran A, Harel M, Cassuto H, Polyansky L, Schnapp A, Wattad N, et al. Cannabinoid treatment for autism: a proof of concept randomized trial. Mol Autism. 2021;12(6):1\u201311. Available from: https:\/\/doi.org\/10.1186\/s13229-021-00420-2","DOI":"10.1186\/s13229-021-00420-2"},{"issue":"6","key":"344_CR2","doi-asserted-by":"publisher","first-page":"E755","DOI":"10.36076\/ppj.20.5.E755","volume":"20","author":"J Aviram","year":"2017","unstructured":"Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20(6):E755-96.","journal-title":"Pain Physician"},{"issue":"360","key":"344_CR3","first-page":"1","volume":"10","author":"J Aviram","year":"2020","unstructured":"Aviram J, Vysotski Y, Berman P, Lewitus GM, Eisenberg E, Meiri D. Migraine frequency decrease following prolonged medical cannabis treatment: a cross - sectional study. Brain Sci. 2020a;10(360):1\u201315.","journal-title":"Brain Sci"},{"issue":"2","key":"344_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/ejp.1675","volume":"25","author":"J Aviram","year":"2020","unstructured":"Aviram J, Pud D, Gershoni T, Schiff Keren B, Ogintz M, Vulfsons S, et al. Medical Cannabis Treatment for Chronic Pain: Outcomes and Prediction of Response. Eur J Pain. 2020b;25(2):359\u201374.","journal-title":"Eur J Pain"},{"issue":"5","key":"344_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/j.pain.0000000000002463","volume":"163","author":"J Aviram","year":"2021","unstructured":"Aviram J, Lewitus G, Vysotski Y, Berman P, Shapira A, Procaccia S, et al. Sex differences in medical cannabis related adverse effects. Pain. 2021;163(5):975\u201383.","journal-title":"Pain"},{"issue":"861037","key":"344_CR6","first-page":"1","volume":"3","author":"J Aviram","year":"2022","unstructured":"Aviram J, Lewitus GM, Vysotski Y, Amna MA, Bar-sela G. The effectiveness and safety of medical cannabis for treating cancer related symptoms in oncology patients. Front Pain Res. 2022a;3(861037):1\u201314.","journal-title":"Front Pain Res"},{"issue":"3","key":"344_CR7","first-page":"1","volume":"7","author":"J Aviram","year":"2022","unstructured":"Aviram J, Atzmony D, Eisenberg E. Long-term effectiveness and safety of medical cannabis administered through the metered-dose Syqe inhaler. Pain Rep. 2022b;7(3):1\u20137.","journal-title":"Pain Rep"},{"issue":"1426","key":"344_CR8","first-page":"1","volume":"16","author":"J Aviram","year":"2023","unstructured":"Aviram J, Glezerman M, Hayam E, Belobrov R, Procaccia S, Meiri D, et al. Evaluating Sex Differences in Efficacy, Safety and Pharmacokinetics in Patients Treated with Cannabis by a Metered-Dose Inhaler. Pharmaceuticals. 2023;16(1426):1\u201315.","journal-title":"Pharmaceuticals"},{"key":"344_CR9","doi-asserted-by":"publisher","unstructured":"Aviram J, Lewitus GM, Pud D, Procaccia S, Berman P, Yellin B, et al. Specific phytocannabinoid compositions are associated with analgesic response and adverse effects in chronic pain patients treated with medical cannabis. Pharmacol Res. 2021;169(105651):1\u201310. Available from: https:\/\/doi.org\/10.1016\/j.phrs.2021.105651","DOI":"10.1016\/j.phrs.2021.105651"},{"key":"344_CR10","doi-asserted-by":"publisher","unstructured":"Aviram J, Atzmony D, Frenklakh A, Kroll A, Zaks I, Hazekamp A. THC degradation does not impair the accuracy of THC doses aerosolized by the metered \u2011 dose SyqeAir inhaler: a 24 \u2011 month stability trial. J Cannabis Res. 2022;4(55):1\u20139. Available from: https:\/\/doi.org\/10.1186\/s42238-022-00166-5","DOI":"10.1186\/s42238-022-00166-5"},{"issue":"1","key":"344_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267420","volume":"18","author":"J Barakji","year":"2023","unstructured":"Barakji J, Korang SK, Feinberg J, Maagaard M, Mathiesen O, Gluud C, et al. Cannabinoids versus placebo for pain: a systematic review with meta-analysis and trial sequential analysis. PLoS One. 2023;18(1):e0267420. https:\/\/doi.org\/10.1371\/journal.pone.0267420.","journal-title":"PLoS One"},{"issue":"827849","key":"344_CR12","first-page":"1","volume":"9","author":"L Bar-Lev Schleider","year":"2022","unstructured":"Bar-Lev Schleider L, Mechoulam R, Sikorin I, Naftali T, Novack V. Adherence, safety, and effectiveness of medical cannabis and epidemiological characteristics of the patient population: a prospective study. Front Med. 2022;9(827849):1\u201314.","journal-title":"Front Med"},{"issue":"1","key":"344_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-32651-4","volume":"8","author":"P Berman","year":"2018","unstructured":"Berman P, Futoran K, Lewitus GM, Mukha D, Benami M, Shlomi T, et al. A new ESI-LC\/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis. Sci Rep. 2018;8(1):1\u201315.","journal-title":"Sci Rep"},{"key":"344_CR14","doi-asserted-by":"crossref","unstructured":"Bhaskar A, Bell A, Boivin M, Briques W, Brown M, Clarke H, et al. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: Results of a modified delphi process. Postgrad Med. 2021;3(22):1\u201312. Available from: https:\/\/www.embase.com\/search\/results?subaction=viewrecord&id=L634270805&from=export%0A10.1080\/00325481.2020.1824967","DOI":"10.1186\/s42238-021-00073-1"},{"issue":"7","key":"344_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M22-0217","volume":"175","author":"KF Boehnke","year":"2022","unstructured":"Boehnke KF, Dean O, Haffajee RL, Hosanagar A. Trends in registration for medical cannabis and reasons for use from 2016 to 2020. Ann Intern Med. 2022;175(7):1\u20138.","journal-title":"Ann Intern Med"},{"issue":"4","key":"344_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.6925","volume":"8","author":"KF Boehnke","year":"2025","unstructured":"Boehnke KF, Sinclair R, Gordon F, Smith T, Roehler DR. Characteristics of medical cannabis patients and clinicians in 7 US states. JAMA Netw Open. 2025;8(4):e256925.","journal-title":"JAMA Netw Open"},{"key":"344_CR17","unstructured":"Brill S, Eisenberg E. Guidelines For Pain Treatment with Medical Cannabis- Israel. 2023."},{"key":"344_CR18","unstructured":"Cannabis magazine. Cannabis magazine website: Maximal monthly MC amounts. 2019 [cited 2025 Jun 20]. Available from:https:\/\/www.xn--4dbcyzi5a.com\/%D7%91%D7%99%D7%94%D7%9E%D7%A9-%D7%90%D7%99%D7%9F-%D7%9C%D7%94%D7%A7%D7%98%D7%99%D7%9F-%D7%9E%D7%99%D7%A0%D7%95%D7%9F-%D7%A7%D7%A0%D7%90%D7%91%D7%99%D7%A1-%D7%A8%D7%A4%D7%95%D7%90%D7%99-%D7%9C\/"},{"key":"344_CR19","unstructured":"Cannabis magazine. Cannabis magazine website: a MC approver physician approval was canceled. 2022 [cited 2025 Jun 20]. Available from:https:\/\/www.xn--4dbcyzi5a.com\/%D7%A1%D7%95%D7%A4%D7%99%D7%AA-%D7%A8%D7%95%D7%A4%D7%90%D7%AA-%D7%94%D7%A7%D7%A0%D7%90%D7%91%D7%99%D7%A1-%D7%9C%D7%90-%D7%AA%D7%95%D7%9B%D7%9C-%D7%9C%D7%94%D7%9E%D7%A9%D7%99%D7%9A-%D7%9C%D7%A0%D7%A4\/"},{"key":"344_CR20","unstructured":"Chambers and Partners. Medical Cannabis & Cannabinoid Regulation 2025: Italy. 2025 [cited 2025 Sep 19]. Available from: https:\/\/practiceguides.chambers.com\/practice-guides\/medical-cannabis-cannabinoid-regulation-2025\/italy\/trends-and-developments"},{"key":"344_CR21","unstructured":"Cohen A. The Marker website: planned MC HMOs prescription reform. 2023 [cited 2025 Jun 20]. Available from: https:\/\/www.themarker.com\/news\/health\/2023-12-04\/ty-article\/0000018c-33ce-d0a6-a19f-bfee5b0a0000"},{"key":"344_CR22","unstructured":"DEA. Drug Enforcement Agency. The Controlled Sub- stances Act. 2018 . Accessed 20 Nov 2024. 2018."},{"issue":"7","key":"344_CR23","first-page":"437","volume":"17","author":"T Ebert","year":"2015","unstructured":"Ebert T, Zolotov Y, Eliav S, Ginzburg O, Shapira I, Magnezi R. Assessment of Israeli Physicians\u2019 Knowledge, Experience and Attitudes towards Medical Cannabis: A Pilot Study. Isr Med Assoc J. 2015;17(7):437\u201341.","journal-title":"Isr Med Assoc J"},{"key":"344_CR24","doi-asserted-by":"publisher","unstructured":"Eisenberg E, Ogintz M, Almog S. The Pharmacokinetics, Efficacy, Safety, and Ease of Use of a Novel Portable Metered-Dose Cannabis Inhaler in Patients With Chronic Neuropathic Pain: A Phase 1a Study. J Pain Palliat Care Pharmacother. 2014;28(3):216\u201325. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/https:\/\/doi.org\/10.3109\/15360288.2014.941130","DOI":"10.3109\/15360288.2014.941130"},{"key":"344_CR25","doi-asserted-by":"publisher","unstructured":"Farber Y, Nir O, Farber S. Medicalization without legalization: the European policy for medical and recreational cannabis use. J Public Health (Bangkok). 2024;1\u20138. Available from: https:\/\/doi.org\/10.1007\/s10389-024-02368-y","DOI":"10.1007\/s10389-024-02368-y"},{"key":"344_CR26","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1111\/dar.14090","volume":"44","author":"D Fortin","year":"2025","unstructured":"Fortin D, Leroy V, Carrieri P, Matias J, Barr\u00e9 T. Relationships between motives for cannabis and cannabidiol use in people who co-use: results from the European web survey on drugs. Drug Alcohol Rev. 2025;44:1666\u201379.","journal-title":"Drug Alcohol Rev"},{"key":"344_CR27","doi-asserted-by":"crossref","unstructured":"Fortin D, Massin S. Medical cannabis: thinking out of the box of the healthcare system. J Gest d\u2019\u00c9conomie la Sant\u00e9. 2020;2(2):110\u2013118. Available from: https:\/\/shs.cairn.info\/article\/JGES_202_0110?tab=resume","DOI":"10.54695\/jges.202.0110"},{"key":"344_CR28","unstructured":"Freedom of information movement. Freedom of information movement website: indications for MC use. 2018 [cited 2025 Jun 20]. Available from: https:\/\/www.odata.org.il\/dataset\/b316eb1b-9e91-4e48-8797-82ce3f957030"},{"issue":"2","key":"344_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1037\/trm0000136","volume":"24","author":"T Green","year":"2017","unstructured":"Green T, Bronstein I, Itzhaky L, Solomon Z. Psychopathology, Risk, and Resilience Under Exposure to Continuous Traumatic Stress: A Systematic Review of Studies Among Adults Living in Southern Israel Article. Traumatology (Tallahass Fla). 2017;24(2):83.","journal-title":"Traumatology (Tallahass Fla)"},{"issue":"4","key":"344_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","volume":"42","author":"F Grotenhermen","year":"2003","unstructured":"Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327\u201360.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"344_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1089\/can.2021.0045","volume":"7","author":"J Guggisberg","year":"2022","unstructured":"Guggisberg J, Schumacher M, Gilmore G, Zylla DM. Cannabis as an anticancer agent: a review of clinical data and assessment of case reports. Cannabis Cannabinoid Res. 2022;7(1):24\u201333.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"375","key":"344_CR32","first-page":"1","volume":"12","author":"M Hacohen","year":"2022","unstructured":"Hacohen M, Stolar OE, Berkovitch M, Elkana O, Kohn E, Hazan A, et al. Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label study. Transl Psychiatry. 2022;12(375):1\u20138.","journal-title":"Transl Psychiatry"},{"issue":"12","key":"344_CR33","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/AJP.0000000000000364","volume":"32","author":"S Haroutounian","year":"2016","unstructured":"Haroutounian S, Meidan R, Davidson E. The effect of medicinal cannabis on pain and quality of life outcomes in chronic pain: a prospective open-label study. Clin J Pain. 2016;32(12):1036\u201343.","journal-title":"Clin J Pain"},{"issue":"9","key":"344_CR34","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/ejp.1297","volume":"22","author":"W H\u00e4user","year":"2018","unstructured":"H\u00e4user W, Finn DP, Kalso E, Krcevski-Skvarc N, Kress HG, Morlion B, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018;22(9):1547\u201364.","journal-title":"Eur J Pain"},{"issue":"951889","key":"344_CR35","first-page":"1","volume":"9","author":"V Hermush","year":"2022","unstructured":"Hermush V, Ore L, Stern N, Mizrahi N, Lederman VE, Schleider LB. Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: a placebo controlled randomized clinical trial. Front Med. 2022;9(951889):1\u201315.","journal-title":"Front Med"},{"issue":"8","key":"344_CR36","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/cbdv.200790152","volume":"4","author":"MA Huestis","year":"2007","unstructured":"Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770\u2013804.","journal-title":"Chem Biodivers"},{"key":"344_CR37","unstructured":"IMOH. IMOH official website: Government resolution #1587 on medical cannabis. 2016 [cited 2025 Jun 20]. Available from: https:\/\/www.gov.il\/en\/pages\/about-yakar"},{"key":"344_CR38","unstructured":"IMOH. Official IMOH website: guidelines of planned MC HMOs prescription reform. 2022 [cited 2022 Jun 20]. Available from: https:\/\/www.gov.il\/he\/pages\/29082022-02"},{"key":"344_CR39","unstructured":"IMOH. Official IMOH website: planned MC HMOs prescription reform. 2023 [cited 2025 Jun 20]. Available from: https:\/\/www.gov.il\/he\/pages\/cn-18122023"},{"key":"344_CR40","unstructured":"IMOH. Official IMOH website: Syllabus for physicians MC training- cycle #16. 2023 [cited 2025 Jun 20]. Available from: https:\/\/ima-contentfiles.s3.amazonaws.com\/SyllabusCanabis_0523.pdf"},{"key":"344_CR41","unstructured":"IMOH. IMOH official website: medical cannabis HMOs prescription reform. IMOH website. 2024 [cited 2025 Jun 20]. Available from: https:\/\/www.gov.il\/he\/pages\/29082022-02"},{"key":"344_CR42","unstructured":"Israeli department of rehabilitation. Official Israeli department of rehabilitation website: MC expenses reimbursement. [cited 2025 Jun 20]. Available from: https:\/\/shikum.mod.gov.il\/medical\/Medicine\/cannabis-buy"},{"key":"344_CR43","unstructured":"Israeli goverment. Israeli goverment official website: public health law. 1994 [cited 2025 Jun 20]. Available from: https:\/\/call.gov.il\/general_content_page\/page\/GE12"},{"key":"344_CR44","unstructured":"Israeli goverment. Israeli goverment official website: Government resolution #3609 on medical cannabis. 2011 [cited 2025 Jun 20]. Available from: https:\/\/www.gov.il\/he\/pages\/2016_dec1587a"},{"key":"344_CR45","unstructured":"Israeli goverment. Israeli goverment official website: Summary of MC pricing comitee discussions. 2019 [cited 2025 Jun 20]. Available from: https:\/\/www.gov.il\/BlobFolder\/dynamiccollectorresultitem\/decision_14012020-b\/he\/decision_and_directives_Decision_14012020_b.pdf"},{"key":"344_CR46","unstructured":"Israeli goverment. Israeli goverment official website: Medicinal Cannabis - An update. Davidovich, Flora K. 2020 [cited 2025 Jun 20]. Available from: https:\/\/main.knesset.gov.il\/EN\/activity\/mmm\/MedicalCannabis-Update.pdf"},{"key":"344_CR47","unstructured":"Israeli goverment. Israeli goverment official website: MC HMOs reform. 2024 [cited 2025 Jun 20]. Available from: www.gov.il\/BlobFolder\/policy\/cn-3103202\/he\/files_circulars_cn_cn-31032024.pdf"},{"key":"344_CR48","unstructured":"Israeli goverment. Israeli goverment official website: overflow of MC flower products from Canada]. 2024 [cited 2025 Jun 20]. Available from: www.gov.il\/BlobFolder\/policy\/dumping-inquiry-cannabis\/he\/dumping_cannabis_cannabis-mikdami-090724.pdf"},{"key":"344_CR49","unstructured":"Israeli Ministry Of Health. External repository website- December 2020 IMCU report screen shots. 2020 [cited 2025 Jun 20]. Available from: https:\/\/www.xn--4dbcyzi5a.com\/%D7%A2%D7%9C%D7%99%D7%99%D7%94-%D7%A9%D7%9C-33-%D7%91%D7%9E%D7%A1%D7%A4%D7%A8-%D7%9E%D7%98%D7%95%D7%A4%D7%9C%D7%99-%D7%94%D7%A7%D7%A0%D7%90%D7%91%D7%99%D7%A1-%D7%91%D7%A9%D7%A0%D7%AA-2020-%D7%A8\/"},{"key":"344_CR50","unstructured":"Israeli Ministry Of Health. External repository website- February 2021 IMCU official report. 2021 [cited 2025 Jun 20]. Available from: www.xn--4dbcyzi5a.com\/wp-content\/uploads\/2021\/03\/licenses-status-february-2021.pdf"},{"key":"344_CR51","unstructured":"Israeli Ministry Of Health. External repository website- March 2021 IMCU official report. 2021 [cited 2025 Jun 20]. Available from: www.xn--4dbcyzi5a.com\/wp-content\/uploads\/2021\/04\/licenses-status-march-2021.pdf"},{"key":"344_CR52","unstructured":"Israeli Ministry Of Health. External repository website- April 2021 IMCU official report. 2021 [cited 2025 Jun 20]. Available from: www.xn--4dbcyzi5a.com\/wp-content\/uploads\/2021\/05\/licenses-status-april-2021.pdf.pdf"},{"key":"344_CR53","unstructured":"Israeli Ministry Of Health. IMCU official website: medical cannabis monthly status. 2025 [cited 2025 Jun 20]. Available from: https:\/\/www.gov.il\/he\/collectors\/publications?officeId=104cb0f4-d65a-4692-b590-94af928c19c0&UnitId=f40553ef-e6a3-4687-82ad-ee05c42a0c40"},{"key":"344_CR54","doi-asserted-by":"publisher","unstructured":"Katsoty D, Greidinger M, Neria Y, Segev A, Lurie I. A prediction model of PTSD in the Israeli population in the aftermath of october 7th, 2023, terrorist attack and the Israel\u2013Hamas war. Isr J Health Policy Res. 2024;13(63):1\u201311. Available from: https:\/\/doi.org\/10.1186\/s13584-024-00644-6","DOI":"10.1186\/s13584-024-00644-6"},{"key":"344_CR55","unstructured":"Landshaft Y, Albo B, Mechoulam R, Afek A. The Updated Green Book (May 2019): The Official Guide to Clinical Care in Medical Cannabis (IMCP-GCP). IMOH website. 2019 [cited 2020 Jun 8]. p. 1\u2013153. Available from: https:\/\/www.health.gov.il\/hozer\/mmk154_2016.pdf"},{"key":"344_CR56","unstructured":"Landshaft Y, Albo B, Mechoulam R, Afek A. The Updated Green Book (May 2021): The Official Guide to Clinical Care in Medical Cannabis (IMCP-GCP). 3rd ed. 2021. 1\u201312 p."},{"key":"344_CR57","unstructured":"Landshaft Y, Zack R, Lazar M, Kagan O, Lavi T. The Updated Green Book (May 2024): The Official Guide to Clinical Care in Medical Cannabis (IMCP-GCP). 2024 p. 1\u201314."},{"issue":"1","key":"344_CR58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jts.23013","volume":"37","author":"AJ Lang","year":"2024","unstructured":"Lang AJ, Hamblen JL, Holtzheimer P, Kelly U, Norman SB, Riggs D, et al. A clinician\u2019s guide to the 2023 VA\/DoD clinical practice guideline for management of posttraumatic stress disorder and acute stress disorder. J Trauma Stress. 2024;37(1):19\u201334.","journal-title":"J Trauma Stress"},{"key":"344_CR59","unstructured":"Levi L. Ynet: physicians arrested in suspition for MC licenses fraud. 2022 [cited 2025 Jun 20]. Available from: www.ynet.co.il\/news\/article\/bj2oygsws"},{"key":"344_CR60","unstructured":"Library of congress. Library of congress official website: Israel- New Directives on Use of Marijuana for Medical Purposes. 2014 [cited 2025 Jun 20]. Available from: https:\/\/www.loc.gov\/item\/global-legal-monitor\/2014-01-06\/israel-new-directives-on-use-of-marijuana-for-medical-purposes"},{"issue":"11","key":"344_CR61","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/bcp.13710","volume":"84","author":"CJ Lucas","year":"2018","unstructured":"Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84(11):2477\u201382.","journal-title":"Br J Clin Pharmacol"},{"key":"344_CR62","unstructured":"MAPS. MAPS official website: The Quiet Giant: Israels Discreet and Successful Medicinal Cannabis Program. [cited 2025 Jun 20]. Available from: https:\/\/maps.org\/news\/media\/the-quiet-giant-israels-discreet-and-successful-medicinal-cannabis-pro"},{"issue":"583605","key":"344_CR63","first-page":"1","volume":"11","author":"L Milay","year":"2020","unstructured":"Milay L, Berman P, Shapira A, Guberman O, Meiri D. Metabolic profiling of Cannabis secondary metabolites for evaluation of optimal postharvest storage conditions. Front Plant Sci. 2020;11(583605):1\u201315.","journal-title":"Front Plant Sci"},{"issue":"11","key":"344_CR64","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/ecco-jcc\/jjab069","volume":"15","author":"T Naftali","year":"2021","unstructured":"Naftali T, Schleider LB-L, Almog S, Meiri D, Konikoff FM. Oral CBD-rich cannabis induces clinical but not endoscopic response in patients with Crohn\u2019s disease, a randomized controlled trial. J Crohns Colitis. 2021;15(11):1799\u2013806.","journal-title":"J Crohns Colitis"},{"key":"344_CR65","unstructured":"National Academies of Sciences Engineering and Medicine. The health effects of cannabis and cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press. Washington (DC), US: Via Medica; 2017 [cited 2025 Jul 23]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28182367\/"},{"issue":"13","key":"344_CR66","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1177\/13591053231173590","volume":"28","author":"V Ne\u2019eman-Haviv","year":"2023","unstructured":"Ne\u2019eman-Haviv V, Rozmann N. Public perceptions of medical cannabis diversion: a legal and moral dilemma. J Health Psychol. 2023;28(13):1264\u201375.","journal-title":"J Health Psychol"},{"key":"344_CR67","unstructured":"NHS. Cannabis-based products for medicinal use. 2019 [cited 2025 Sep 19]. Available from: https:\/\/www.england.nhs.uk\/medicines-2\/support-for-prescribers\/cannabis-based-products-for-medicinal-use"},{"key":"344_CR68","unstructured":"NICE. Cannabis-based medicinal products: NICE guideline NG144. 2021 [cited 2025 Sep 19]. Available from: https:\/\/www.nice.org.uk\/guidance"},{"key":"344_CR69","unstructured":"Patil I, Powell C. ggstatsplot: \u201cggplot2\u201d Based Plots with Statistical Details. 2008 [cited 2019 Dec 1]. Available from: https:\/\/cran.r-project.org\/web\/packages\/ggplot2\/ggplot2.pdf"},{"key":"344_CR70","unstructured":"Pilot A. Calcalist website: MC import permitted to Israel on the first time. 2019 [cited 2025 Jun 20]. Available from: https:\/\/www.calcalist.co.il\/local\/articles\/0,7340,L-3775454,00.html"},{"issue":"1","key":"344_CR71","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/can.2019.0010","volume":"4","author":"D Piomelli","year":"2019","unstructured":"Piomelli D, Solomon R, Abrams D, Balla A, Grant I, Marcotte T, et al. Regulatory barriers to research on cannabis and cannabinoids: a proposed path forward. Cannabis Cannabinoid Res. 2019;4(1):21\u201332.","journal-title":"Cannabis Cannabinoid Res"},{"key":"344_CR72","doi-asserted-by":"crossref","unstructured":"Pud D, Aamar S, Schiff-keren B, Sheinfeld R, Brill S, Robinson D, et al. Cannabis oil extracts for chronic pain: what else can be learned from another structured prospective cohort? Pain reports. 2024;e1143:1\u20136.","DOI":"10.1097\/PR9.0000000000001143"},{"key":"344_CR73","unstructured":"QCQ. Cannabis-based medicinal products: what we look at when we register and inspect. 2025 [cited 2025 Sep 19]. Available from: https:\/\/www.cqc.org.uk\/guidance-providers\/healthcare\/cannabis-based-medicinal-products-what-we-look-when-we-register"},{"key":"344_CR74","doi-asserted-by":"publisher","unstructured":"Raz N, Eyal AM, Zeitouni DB, Hen-shoval D, Davidson EM, Danieli A, et al. Selected Cannabis Terpens Synergize with THC to Produce Increased CB1 Receptor Activision. Biochem Pharmacol. 2023;212(115548):1\u201346. Available from: https:\/\/doi.org\/10.1016\/j.bcp.2023.115548","DOI":"10.1016\/j.bcp.2023.115548"},{"issue":"4","key":"344_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5041\/RMMJ.10485","volume":"13","author":"D Robinson","year":"2022","unstructured":"Robinson D, Ritter S, Yassin M. Comparing sublingual and inhaled Cannabis therapies for low back pain: an observational open-label study. Rambam Maimonides Med J. 2022;13(4):1\u201312.","journal-title":"Rambam Maimonides Med J"},{"issue":"6","key":"344_CR76","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3390\/jcm8060807","volume":"8","author":"I Sagy","year":"2019","unstructured":"Sagy I, Bar-Lev Schleider L, Abu-Shakra M, Novack V. Safety and efficacy of medical cannabis in fibromyalgia. J Clin Med. 2019;8(6):807\u201319.","journal-title":"J Clin Med"},{"key":"344_CR77","doi-asserted-by":"publisher","unstructured":"Sagy YW, Ramot N, Battat E, Arbel R, Reges O, Dicker D, et al. Articles Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational , retrospective cohort study. eClinicalMedicine. 2025;83(May):103213. Available from: https:\/\/doi.org\/10.1016\/j.eclinm.2025.103213","DOI":"10.1016\/j.eclinm.2025.103213"},{"key":"344_CR78","doi-asserted-by":"crossref","unstructured":"Schleider LB-L, Mechoulam R, Lederman V, Hilou M, Lencovsky O, Betzalel O, et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med. 2018;49:37\u201343.","DOI":"10.1016\/j.ejim.2018.01.023"},{"key":"344_CR79","doi-asserted-by":"crossref","unstructured":"Schnapp A, Harel M, Cayam-Rand D, Cassuto H, Polyansky L, Aran A. A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ. Biomedicines. 2022 [cited 2022 Jul 21];10(7):1685. Available from: https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1685","DOI":"10.3390\/biomedicines10071685"},{"key":"344_CR80","doi-asserted-by":"crossref","unstructured":"Shapira A, Berman P, Futoran K, Guberman O, Meiri D. Tandem mass spectrometric quantification of 93 terpenoids in Cannabis using static headspace (SHS) injections. Anal Chem. 2019 [cited 2019 Aug 7];91(17):1\u20139. Available from: https:\/\/pubs-acs-org.ezlibrary.technion.ac.il\/doi\/pdf\/10.1021\/acs.analchem.9b02844?rand=1gmatc96","DOI":"10.1021\/acs.analchem.9b02844"},{"issue":"3903720","key":"344_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/3903720","volume":"1","author":"H Sharon","year":"2022","unstructured":"Sharon H, Greener H, Hochberg U, Brill S. The Prevalence of Chronic Pain in the Adult Population in Israel: An Internet-Based Survey. Pain Res Manag. 2022;1(3903720):1\u20137.","journal-title":"Pain Res Manag"},{"issue":"1","key":"344_CR82","first-page":"59","volume":"2","author":"Z Solomon","year":"1989","unstructured":"Solomon Z. A 3-year prospective study of post-traumatic stress disorder in Israeli combat veterans. J Trauma Stress. 1989;2(1):59\u201373.","journal-title":"J Trauma Stress"},{"key":"344_CR83","doi-asserted-by":"crossref","unstructured":"Str\u00f6bel A, Haynes A. R package atable: Create Tables for Reporting Clinical Trials. Version 0.1.5. Comprehensive R Archive Network (CRAN). Comprehensive R Archive Network (CRAN); 2019 [cited 2019 Dec 1]. Available from: https:\/\/cran.r-project.org\/web\/packages\/atable\/atable.pdf","DOI":"10.32614\/CRAN.package.atable"},{"issue":"6","key":"344_CR84","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/dar.13116","volume":"39","author":"SR Sznitman","year":"2020","unstructured":"Sznitman SR. Trends in medical cannabis licensure, Israel, 2013\u20132018. Drug Alcohol Rev. 2020;39(6):763\u20137.","journal-title":"Drug Alcohol Rev"},{"key":"344_CR85","unstructured":"The Washingtom Post. The Washingtom Post website: Israeli medical marijuana creates buzz but no high\u2014 will it go global? 2015 [cited 2025 Jun 20]. Available from: https:\/\/www.washingtonpost.com\/world\/middle_east\/israeli-medical-marijuana-creates-buzz-but-no-high-will-it-go-global\/2015\/01\/31\/558fe072-a19a-11e4-9f89-561284a573f8_story.html"},{"key":"344_CR86","unstructured":"US Department of Veterans Affairs. VA and Marijuana \u2013 What Veterans need to know. 2023 [cited 2025 Sep 19]. Available from: https:\/\/www.publichealth.va.gov\/marijuana.asp"},{"key":"344_CR87","unstructured":"Wickham H. Tidyverse: Easily install and load \u2019Tidyverse\" packages. Version 1.3.0. Comprehensive R Archive Network (CRAN). 2019. Available from: https:\/\/cran.r-project.org\/web\/packages\/tidyverse\/tidyverse.pdf"},{"key":"344_CR88","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.drugpo.2017.07.032","volume":"49","author":"D Zarhin","year":"2017","unstructured":"Zarhin D, Negev M, Vulfsons S, Szintman S. Medicalization of cannabis: what does it mean? Int J Drug Policy. 2017;49:54\u20137.","journal-title":"Int J Drug Policy"},{"key":"344_CR89","doi-asserted-by":"publisher","unstructured":"Zolotov Y, Grinstein Cohen O, Findley PA, Reznik A, Isralowitz R, Willard S. Attitudes and knowledge about medical cannabis among Israeli and American nursing students. Nurse Educ Today. 2021 [cited 2021 Feb 1];99(104789):1\u201326. Available from: https:\/\/doi.org\/10.1016\/j.nedt.2021.104789","DOI":"10.1016\/j.nedt.2021.104789"}],"container-title":["Journal of Cannabis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-025-00344-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42238-025-00344-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-025-00344-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:58:10Z","timestamp":1781614690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42238-025-00344-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["344"],"URL":"https:\/\/doi.org\/10.1186\/s42238-025-00344-1","relation":{},"ISSN":["2522-5782"],"issn-type":[{"value":"2522-5782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study involved secondary analysis of publicly available, de-identified data published by the Israeli Medical Cannabis Unit (IMCU). No human participants, human tissue, or personal identifying information were involved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}